Fiera Capital Corp Reduces Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Fiera Capital Corp cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 39.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,212,561 shares of the biopharmaceutical company's stock after selling 2,067,881 shares during the quarter. Fiera Capital Corp owned 1.08% of Amicus Therapeutics worth $34,310,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Hazlett Burt & Watson Inc. lifted its holdings in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,569 shares during the period. Blue Trust Inc. lifted its holdings in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new stake in Amicus Therapeutics in the 3rd quarter worth approximately $32,000. Headlands Technologies LLC purchased a new stake in Amicus Therapeutics in the 2nd quarter worth approximately $89,000. Finally, Sage Capital Advisors llc purchased a new stake in Amicus Therapeutics in the 2nd quarter worth approximately $103,000.

Analyst Ratings Changes

Several equities research analysts have weighed in on FOLD shares. Bank of America increased their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, October 17th. Guggenheim raised their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday. JPMorgan Chase & Co. reduced their target price on Amicus Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a report on Friday, August 16th. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Friday. Finally, Jefferies Financial Group started coverage on Amicus Therapeutics in a report on Friday, September 6th. They issued a "buy" rating and a $18.00 target price for the company. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Amicus Therapeutics has an average rating of "Moderate Buy" and an average price target of $17.50.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total transaction of $98,762.50. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $11,083,175. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Bradley L. Campbell sold 7,901 shares of the firm's stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the transaction, the chief executive officer now owns 886,654 shares of the company's stock, valued at $11,083,175. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bradley L. Campbell sold 7,500 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,398,532.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,401 shares of company stock worth $352,038 in the last ninety days. Insiders own 2.20% of the company's stock.

Amicus Therapeutics Trading Up 0.1 %

Shares of FOLD stock traded up $0.01 on Friday, reaching $10.99. The stock had a trading volume of 2,096,772 shares, compared to its average volume of 2,700,833. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The company has a 50 day simple moving average of $11.13 and a 200 day simple moving average of $10.61.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. Amicus Therapeutics had a negative return on equity of 17.03% and a negative net margin of 21.21%. The company's revenue for the quarter was up 34.0% on a year-over-year basis. During the same period last year, the business posted ($0.15) EPS. Equities analysts forecast that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.